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Background: Several lines of evidence have demonstrated that bone marrow-derived mesenchymal stem cells
(BM-MSC) release bioactive factors and provide neuroprotection for CNS injury. However, it remains elusive whether
BM-MSC derived from healthy donors or stroke patients provides equal therapeutic potential. The present work aims
to characterize BM-MSC prepared from normal healthy rats (NormBM-MSC) and cerebral ischemia rats (IschBM-MSC),
and examine the effects of their conditioned medium (Cm) on ischemic stroke animal model.
Results: Isolated NormBM-MSC or IschBM-MSC formed fibroblastic like morphology and expressed CD29, CD90 and
CD44 but failed to express the hematopoietic marker CD34. The number of colony formation of BM-MSC was more
abundant in IschBM-MSC than in NormBM-MSC. This is in contrast to the amount of Ficoll-fractionated mononuclear
cells from normal donor and ischemic rats. The effect of cm of BM-MSC was further examined in cultures and in middle
cerebral artery occlusion (MCAo) animal model. Both NormBM-MSC Cm and IschBM-MSC Cm effectively increased
neuronal connection and survival in mixed neuron-glial cultures. In vivo, intravenous infusion of NormBM-MSC Cm and
IschBM-MSC Cm after stroke onset remarkably improved functional recovery. Furthermore, NormBM-MSC Cm and
IschBM-MSC Cm increased neurogenesis and attenuated microglia/ macrophage infiltration in MCAo rat brains.
Conclusions: Our data suggest equal effectiveness of BM-MSC Cm derived from ischemic animals or from a normal
population. Our results thus revealed the potential of BM-MSC Cm on treatment of ischemic stroke.
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Cell surface markersBackground
Ischemic stroke is one of the world’s fastest-growing
diseases with high mortality and the leading cause of
long-term disability worldwide [1]. There is no effective
treatment available for either focal cerebral ischemia or
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stated.plasminogen activator (rt-PA) therapy directed at the dis-
solution of thrombi in affected blood vessel in adult fol-
lowing stroke [2]. A major limitation of r-tPA therapy for
acute stroke is its narrow therapeutic window of 4.5 hours
after stroke onset [1]. Beyond this timing of administra-
tion, rt-PA presents with deleterious side effects, in par-
ticular increase risk of intra-cerebral hemorrhage which
can exacerbate stroke injury and counteract the benefits
provided by reperfusion of the occluded artery in many
patients [3].
There is increasing evidence that the transplanted
bone marrow mesenchymal stem cell (BM-MSC) signifi-
cantly promote functional recovery after central nervous. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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kinds of CNS disorders, including ischemic stroke [4]. In
the ischemic stroke animal model, BM-MSC transplant-
ation has been demonstrated to reduce cell apoptosis
[5], induce angiogenesis [6], promote endogenous cell
proliferation [7], and enhance axonal remodeling [8]. Re-
cently, transplantation of BM-MSC was shown to
achieve clinical efficacy in patients with ischemic stroke
[9,10]. However, it is unclear what brings about the pur-
ported benefit from BM-MSC transplantation. The main
goal of early BM-MSC studies in stroke was to differen-
tiate into neurons and replace the injured neuron in in-
farct area [11,12]. However, very few transplanted cells
were found in the brain and of these, only a small per-
centage cells expressed neuronal cell markers [13,14]. In
addition, expression of neuronal cell markers did not in-
dicate true differentiation and with neuronal cell func-
tion. Moreover, after BM-MSC transplantation, these
cells, even differentiated cells, are very unlikely to have
truly integrated into parenchymal tissue and form the
complex connections that promote functional recovery
[13]. Hence, it is unlikely that transplanted BM-MSC act
to replace the damaged tissue. It is more feasible that
BM-MSC might create a favorable environment for re-
generation, and expression of beneficial bioactive factors.
BM-MSC grafts have been shown to increase expression
of several cytokines, neurotrophins and growth factors
in ischemic brains. These include brain-derived neuro-
trophic factor (BDNF), glial cell-derived neurotrophic
factor (GDNF), nerve growth factor (NGF), [13] , IGF-1
[15], stromal cell-derived factor-1 (SDF-1) [16], basic
fibroblast growth factor (bFGF) and vascular endothelial
growth factor (VEGF) [17], and all are responsible for
the beneficial effects of BM-MSC against ischemic stroke
on brain protection and tissue regeneration.
Recent studies suggested that hypoxic preconditioning of
BM-MSC significantly enhanced homing of transplanted
cells to the ischemic region and effectively promoted the
regenerative capability and therapeutic potential of BM-
MSC for the treatment of ischemic stroke [18,19]. How-
ever, it remains elucidated whether BM-MSC derived from
healthy donors or stroke patients provides equal thera-
peutic potential. The present work aims to characterize
BM-MSC obtained from normal healthy rats and cerebral
ischemia rats, and examine the effects of their conditioned
medium (Cm) on ischemic stroke animal model.
Methods
Reagents and antibodies
Cultured medium, fetal bovine serum (FBS), serum-free
supplements and antibiotics were purchased from Gibco
(Carlsbad, CA, USA). Antibodies used in this study are
listed as follows: rabbit anti-betaIII tubulin (Upstate
Biotechnology, Lake Placid, NY, USA), mouse anti-ED1(CD68) (Serotec, England, UK), goat anti-doublecortin
(DCX, Chemicon, Merck Millipore), mouse anti-BrdU
(Chemicon, Merck Millipore), mouse anti-CD90-PE (BD
biosciences), mouse anti-CD44-FITC (BD biosciences),
mouse anti-CD34-FITC (BD biosciences); mouse anti-
CD29-FITC (BD biosciences). Unless stated otherwise, all
other chemicals were purchased from Sigma-Aldrich Co.
Animal surgery and treatment
Adult male Long Evan (LE) rats (6–8 weeks old; 250–
350 g) were obtained from National Laboratory Animal
Center, Taiwan. All efforts were taken to minimize animal
suffering during and following surgery. Middle cerebral ar-
terial occlusion (MCAo) surgery was used for creating focal
cerebral ischemic injury. Focal cerebral ischemic injury was
produced in the right lateral cerebral cortex by permanent
ligation of MCA with 10–0 monofilament nylon. Both
common carotid arteries were clamped for 60 minutes and
then reperfusion of flow was confirmed visually during sur-
gery before closure of the wound. BM-MSC Cm was intra-
venously infused to MCAo rats immediately after blood
reperfusion. The functional motor deficits in experimental
rats were quantified at 1, 3, 7 days post-injury. Measures of
brain infarction and histochemical staining were conducted
at 1 week after right MCA occlusion.
Isolation and expansion of mesenchymal stem cells from
bone marrow
Bone marrows were aspirated from femur bones of nor-
mal or post 1 week-MCAo adult LE rats. Bone marrow
cells were flushed out from femurs with phosphate buff-
ered saline (PBS; GIBCO) and filtered through nylon
cloths (70 μm sieve). The filtered cells were collected by
centrifugation (326 × g for 10 minutes), resuspended
and diluted with equal volume of Dulbecco’s modified
Eagle’s medium containing F12 (DMEM/F12). The resulted
cell suspension was layered onto Ficoll-paque solution
(1.077 g/mL) and centrifuged to deplete the residues of
red blood cells, platelets, and plasma. Ficoll-fractionated
mononuclear cells were recovered from the gradient inter-
face. The isolated cells were washed once, seeded in
75 cm2 flask (Falcon) and maintained in DMEM/F12
supplemented with 10% fetal calf serum (FCS), 100 U/mL
penicillin and 100 μg/mL streptomycin at 37°C in a water-
saturated atmosphere of 5% CO2/95% air. Non-adherent
cells were removed at 2 days after initial seeding. Cul-
tures developed colonies of fibroblast-like cells (CFU-f)
within 2 weeks. The attached cells at about 80% con-
fluence were subcultured and expanded. Cultured cells
were phenotypically characterized by flow cytometric
analysis. The proliferative activities of cultured cells were
investigated by pulsing subconfluent cells with 10 uM
5-bromo-2’-deoxyuridine (BrdU; Sigma) for 3 hours. The
cells were then fixed and immunostained with anti-BrdU,
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(Sigma).
Immunophenotypic analyses of expressed antigens on
cell surface
For further characterization, cell surface antigen pheno-
typing was performed on isolated and expanded bone
marrow cells were detected at passages 0 to 3 by flow
cytometric analysis. The adherent cells were harvested
by treatment of 5 mM EDTA in PBS solution. Cells were
stained for 1 hour on ice with fluorescein isothiocyanate
(FITC)- or phycoerythrin (PE)-conjugated anti-marker
monoclonal antibodies. Antibodies used for specific surface
markers included hematopoietic lineage early marker
(CD34), Thy-1 (CD90), integrin (CD29) and CD44. The
stained cells were subsequently analyzed by fluorescence-
activated cell sorter (FACS Calibur flow cytometer; BD
bioscience) using a 525 nm band-pass filter for green
FITC fluorescence and a 575 nm band-pass filter for red
PE fluorescence.
Preparation of conditioned medium of bone marrow
mesenchymal stem cells (BM-MSC Cm)
Second to third passages BM-MSC were processed for BM-
MSC Cm collection. When cultures reached ~80% conflu-
ence, cultures were washed trice with PBS and refilled with
DMEM/F12 supplemented with 2% LE rat serum. The cm
was collected after incubation with BM-MSC for 24 hours.
BM-MSC Cm were further concentrated with a centrifugal
filter device (5 kDa cut-off, Amicon Ultra, Millipore). The
resulted cm (~10 fold concentrated) of BM-MSC were
preserved at −80°C until use.
Behavioral test
Functional behaviors in rats were tested at 1, 3, 5 and
7 post-injury or before sacrifice. Contralateral motor
deficits in the rat forelimbs due to the damage of
stroke–affected brain were evaluated using grasping
power test [20,21]. The grasping power test is a modifi-
cation of the method of Bertelli and Mira [20] using a
commercial grip-strength meter (Grip-strength- meter
303500, TSE systems Corp) for rats. Both forepaws
were tested, testing one forepaw at a time. The untested
forepaw was temporarily prevented from grasping by
wrapping it with adhesive tape, and the tested forepaw
was kept free. The rats were allowed to grasp the bar
while being lifted by the tail with increasing firmness
until they loosened their grip, and the grasping power
was scored.
Morphological analysis
Rats were sacrificed at one week after ischemia-reperfusion
for infarct volume analysis (by 2,3,5-triphenyltetrazolium
chloride (TTC) staining) and immune histochemistry(IHC). For TTC staining, rat brains were quickly removed,
placed to a brain matrix slicer (Jacobowitz Systems,
Zivic-Miller Laboratories Inc., Allison Park, PA, USA)
and sectioned into 2 mm coronal slices. The resulted
slices were stained with 2% TTC for 30 min and fixed in
10% buffered formalin solution overnight. TTC positive
staining, indicating viable tissues, was used to verify suc-
cessful stroke and treatment. Infarct volumes (negative
TTC staining area) were analyzed using AIS imaging re-
search software (Imaging Research Inc., St. Catharines,
Ontario, Canada). The area of infarction was measured
by subtracting the area of the non-lesioned ipsilateral
hemisphere from that of the contralateral side plus nega-
tive TTC staining area. Infarct volume was calculated as
the sum of infarct area per slice multiplied by slice thick-
ness [22]. Both the surgeon and image analyzer operator
were blinded to the treatment given each animal. The
conditioned medium is blind to the surgeon and operator
too. For fluorescence immunocytochemical staining, the
tissues were post-fixed with 4% paraformaldhyde, proc-
essed in series with 15% and 30% sucrose and finally
embedded in OCT compound (Sakura Fine Technical,
Tokyo, Japan). Tissues were cut into serial 10 μm sec-
tions with a cryostat. Immunocytochemical staining was
performed on serial sections as described in our previ-
ously published papers [23]. Images of immunoreactive
cells in brain sections were obtained with a fluorescent
microscope equipped with fluorescence optics and with a
CCD camera.
Cortical neuronal cultures
Cortical neuronal cultures were prepared from the cere-
brocortical regions of Sprague–Dawley (SD) rat fetuses
at gestation 15–17 days as described in Tsai et al.
[24-26]. In brief, fetal cortexes were dissociated with
mixtures of papain/protease/deoxyribonuclease I (0.1%:
0.1%: 0.03%). Cultures were plated onto poly-D-lysine
coated multi-well plates and maintained in Dulbecco’s
modified Eagle’s medium (DMEM, Gibco) with 10% FBS
at 37°C in a water-saturated atmosphere of 5% CO2 and
95% mixed air. Second day after cell seeding, aliquots of
NormBM-MSC Cm or IschBM-MSC Cm was added to
neuronal culture and incubated for 3 days. Culture
medium was then collected for lactate dehydrogenase
(LDH) assay and cells were fixed for immunofluorescent
staining. For quantitative analysis of neurite density, 20
images per condition were obtained. Neurite density was
analyzed using ImageJ software (NIH systems). A com-
mercial kit (CellTiter 96 Aqueous; Promega Corpor-
ation) was used for determining the extent of cell
survival as cytosolic LDH release in cultured medium.
Activity of LDH in the medium was determined by the
reduction of MTS tetrazolium into colored formazan
products and measure absorbance at 490 nm.
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All measurements were performed blind to each group. Ex-
perimental data were expressed as the mean of independent
values ± s.e.m. and were analyzed using one-way analysis of
variance (ANOVA) followed by Bonferroni’s t-test. P values
less than 0.05 were considered statistically significant.
Results
Characterization of BM-MSC cultured from normal or
ischemic rats
We first characterized the cells and cultures prepared
from normal or post-MCAo LE rat bone marrow. ThisFigure 1 Characterization of BM-MSC cultured from normal or ischem
and IschBM-MSC, respectively. (C,D) Proliferative activities of NormBM-MSC
and Hoechst (blue) incorporation. Magnification: 200× (E) Ficoll-fractionate
ischemic rats. n = 13 ~ 16; *P < 0.05 (F) Numbers of colony forming unit-fib
n = 4 per group; *p < 0.05 IschBM-MSC vs. NormBM-MSC (G) Quantitative cdata was calculated from Ficoll-separated bone marrow
cells from 13–16 rats. After Ficoll-paque centrifugation,
mononuclear cells of bone marrow were aspirated from
the density interface (1.077 g/ml, lymphocytic layer), pel-
leted and washed twice with PBS. The resulted cells
were counted before seeding for adherent cultures (BM-
MSC). Figure 1E shows that Ficoll-fractionated mono-
nuclear cells from normal rats were significantly more
abundant than that from ischemic rats (p < 0.05). BM-
MSC, also referred to as colony-forming fibroblast
(CFU), are able to form round-shape colonies of fibro-
blastic like cells, namely CFU-f [27,28]. Figure 1A and Bic rats. (A,B) round-shape colonies of fibroblastic like NormBM-MSC
and IschBM-MSC were stained with anti-BrdU labeled FITC (green)
d mononuclear cell numbers from bone marrows of normal or
roblast (CFU-f) from bone marrow cultures at 6 and 14 days in vitro.
ell proliferation of NormBM-MSC and IschBM-MSC.
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MSC with similar morphology. Colonies appear as a
central core of round cells surrounded by more elon-
gated cells at the periphery. Because the number of
colonies is an index of MSC functional capacity, clones
of >50 fibroblasts (as fibroblastic colony) from NormBM-
MSC and IschBM-MSC were scored at 6 days and 14
days after initial seeding. As the quantitative results,
these expanded BM-MSC increased the number of col-
onies over time (Figure 1F). Interestingly, IschBM-MSC
possessed higher frequency of CFU-f than NormBM-
MSC (day 6: 1.75 ± 1.70 and 7.50 ± 3.10 colonies per 75 T
flask in NormBM-MSC and IschBM-MSC, respectively;
day 14: 25.75 ± 10.60 and 48.25 ± 14.40 colonies per
T75 flask in NormBM-MSC and IschBM-MSC, re-
spectively; n = 4 per group; p < 0.05). To investigate
whether proliferative ability of BM-MSC rendering differ-
ent CFU-f in NormBM-MSC and IschBM-MSC, in vitro
BrdU incorporation was conducted in cells after subcul-
ture. As the immunocytochemical result, the number of
BrdU-positive cells increased in the IschBM-MSC group
(Figure 1D), with a definite trend, compared with the
NormBM-MSC group (Figure 1C). Primary cultures of
BMSC from normal or ischemic rats reach ~80% con-
fluence at definite periods, in vitro BrdU incorporation
was analyzed after cell passage. The quantitative ratio of
BrdU (+) cells/Hoechst in both cultures were shown in
Figure 1G. These results indicate that IschBM-MSC can
be expanded rapidly ex vivo and might be more available
to provide cell therapy for stroke.
Characterization surface protein expression of BM-MSC
cultured from normal or ischemic rats
For further characterization of the BM-MSC, surface
protein expression of BM-MSC of isolated and expanded
cells was carried out using fluorescence-activated cell
sorting (FACS) analysis at cell passages 0 to 3. Figures 2A
and B showed that more than 98% of isolated NormBM-
MSC or IschBM-MSC expressed typical MSC marker
protein, β1-integrin (CD29) and Thy1 (CD90). Approxi-
mate >90% CD44-positive cells existed in NormBM-
MSC and IschBM-MSC population. By contrast, both
cultures failed to express immunoreactivity (IR) to
CD34, a surface marker for early hematopoietic stem
cells. Figure 2C shows that there was no significant dif-
ference in cytometric analysis of cell surface markers be-
tween NormBM-MSC and IschBM-MSC at the second
passage. Figure 2D and E show similar total cell popula-
tions by FACS analyses in cultured NormBM-MSC (D)
and IschBM-MSC (E). We also evaluated the soluble fac-
tors released from BM-MSC by zymography and western
blot analysis. Additional file 1: Figure S1 (C) shows west-
ern blot identification of 5 factors, including aFGF,
TIMP1, IGFBP4, VEGF (in non-reduced form) and SCF,which exist at similar levels between NormBM-MSC Cm
and IschBM-MSC Cm. Furthermore, SDS gel and zymo-
graphic results (detecting activities of MMP2 and MMP9)
in both Cm have similar patterns.
Effects of Cm from NormBM-MSC and IschBM-MSC on
neuronal survival
Three days after treatment, cortical cell cultures were im-
munostained with anti-βIII-tubulin, a neuronal marker
and medium were collected for LDH assay. Compared to
control cultures, both NormBM-MSC Cm and IschBM-
MSC Cm increased neuronal connection, as shown in
Figure 3A-C. Quantitative results of betaIII tubulin immu-
noreactivity by Image J further shows that neuronal density
was significantly enhanced by the treatment of NormBM-
MSC Cm or IschBM-MSC Cm (Figure 3D). Release of
cytosolic lactate dehydrogenase (LDH) is a hallmark
of destroyed cells. Figure 3E shows that the percentage of
cytosolic LDH release was significantly reduced in the
treatment with NormBM-MSC Cm and IschBM-MSC Cm
compared with medium control (100%). Thus, these results
suggest that NormBM-MSC Cm and IschBM-MSC Cm
promoted cell integrity and might decrease cell sus-
ceptibility after CNS injury.
Effects of Cm from NormBM-MSC and IschBM-MSC on rat
ischemic stroke
We determined the effect of cm from NormBM-MSC
and IschBM-MSC in reducing brain infarction after is-
chemic stroke in rats. Results showed that NormBM-
MSC Cm and IschBM-MSC Cm decreased brain infarc-
tion caused by 60-min MCAo and following reperfusion
for 7 days based on quantification of TTC staining of
brain slices; however, statistical significance was not
achieved (Figure 4A-C). In addition to the extent of
brain infarction, behavioral deficits in the MCAo-treated
rats with or without cm were examined. The grasping
power of the left forepaws of rats before MCAo or that
of the right forepaws of rats before or at the end of the 7
days post-MCAo (Figure 4D-E) did not differ among
these groups. Interestingly, MCAo significantly de-
creased grasping power that was improved by adminis-
tration of NormBM-MSC Cm and IschBM-MSC Cm at
the end of the 7 days post-MCAo (Figure 4D).
Effects of Cm from NormBM-MSC and IschBM-MSC on
neurogenesis in vivo
Results that NormBM-MSC Cm and IschBM-MSC Cm
improved functional outcome without a significant reduc-
tion in infarct volume suggest mechanisms other than
neuroprotection may contribute to the observed func-
tional improvement. To examine the effect of NormBM-
MSC and IschBM-MSC on the survival or proliferation of
progenitor cells and/or immature neurons in the ischemic
Figure 2 Flow cytometry analysis of bone marrow mesenchymal stem cells (BM-MSC) from normal and cerebral ischemic rats. (A)
analysis of cell surface markers in NormBM-MSC (B) analysis of cell surface markers in ischBM-BMSC (C) comparative analysis of cell surface
markers in NormBM-MSC and IschBM-MSC (D-E) FACS analyses of total cell populations in cultured NormBM-MSC (D) and IschBM-MSC (E). Cells
(passages 1-3) were lifted, labeled with antibodies against the indicated antigens, and analyzed by flow cytometry. Only representative examples
featuring antigen expression profiles are shown. Abbreviations: FITC, fluorescein isothiocyanate; PE, phycoerythrin.
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for doublecortin (DCX) at seven days after MCAo. DCX
is a marker for neuronal progenitor cells and immature
neurons to evaluate neuronal plasticity. Figure 5A and 5B
showed that application of NormBM-MSC Cm and
IschBM-MSC Cm enhanced the extent of DCX-positive
cells in the lateral ventricular area of stroke-affectedhemispheres, indicating a heightened generation of neural
progenitor cells.
Effects of Cm from NormBM-MSC and IschBM-MSC on
microglia/macrophage infiltration in vivo
We performed fluorescence immunohistochemistry for
ED1, a marker for activated microglia and macrophage,
Figure 3 Conditioned medium from NormBM-MSC or IschBM-MSC increased cortical neuronal survival by enhancing neuronal connection
and decreasing LDH release. (A) Neuronal cells, non-treated control. (B) NormBM-MSC Cm-treated neuronal cells (C) IschBM-MSC Cm-treated neuronal
cells (D) βIII tubulin positive signal, as percentage of total area, quantified by Image J, in cortical neuronal cells. (E) LDH release to medium in cortical
neuronal cells. Three days after treatment, cortical cell cultures were immunostained with anti-βIII-tubulin, a neuronal marker and medium were collected
for LDH assay. Data are presented as means ± SEM from 8–10 independent experiments done in duplicate. *, **P < 0.05, 0.01 Treatment versus control.
Magnification 200× (A-C).
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MCAo. Immunostaining results showed that a large
number of ED1-positive cells were located on the ische-
mic core and the ischemic boundary zone of the stroke-
affected cortices at seven days after MCAo in the
medium control group (Figure 6A). By contrast, only a
few ED1-positive cells were observed in the ischemic
cortex in the group receiving NormBM-MSC Cm or
IschBM-MSC Cm (Figure 6A). Quantitative analysis
exactly confirmed that MCAo rats receiving NormBM-
MSC Cm or IschBM-MSC Cm significantly reduced
accumulation of ED1-positive cells (Figure 6B). Thus,
these observations suggest that the intervention with
NormBM-MSC Cm and IschBM-MSC Cm minimizes
pro-inflammatory cascades during cerebral ischemia, at
least in part, via attenuating microglia/macrophage
infiltration.Discussion and conclusions
In current study, we are the first to compare the effects
of treatment of ischemic stroke with NormBM-MSC Cm
or IschBM-MSC Cm. We presented experimental evi-
dence supporting the notion that administration of
NormBM-MSC Cm or IschBM-MSC Cm may reduce
the extents of brain injury in vivo and in vitro. Further-
more, our data suggests that enhancement of neurogen-
esis and attenuation of microglia/macrophage infiltration
may contribute to the underlying beneficial effect of
NormBM-MSC Cm and IschBM-MSC Cm.
We first compared the characteristics of NormBM-
MSCs and IschBM-MSCs. In the present study, we
found that the typical colonies of NormBM-MSC and
IschBM-MSC with similar morphology and there was no
significant difference in the expression of cell surface
markers between NormBM-MSC and IschBM-MSC.
Figure 4 Effects of administration of conditioned medium from NormBM-MSC and IschBM-MSC on infarct volume and functional
behavior in MCAo rats. (A) The right lateral view of MCAo rat brains showing the stroke outcome from different treatments, (B) The infarct
volumes of MCAo rat brains evaluated at 7 days postinjury using TTC staining analysis (C) Quantitative results of TTC staining of MCAo rat brains
from different treatment, These results were taken as the mean ± S.D. from 8 ~ 15 rats/group (Control n = 8, NormBM-MSC Cm n = 15, IschBM-MSC
n = 9), (D) Grip strength of left forelimbs (g) assessed using grasping power test on stroke-affected side (#p < 0.05 versus pre-MCAo, *p < 0.05 versus
Control), (E) Grip strength of right forelimbs (unaffected side). Data were given as the mean ± S.D. from 6 ~ 7 rats/group (7 rats for control, 6 rats for
NormBM-MSC Cm and 6 rats for IschBM-MSC Cm).
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were significantly more abundant than that from ische-
mic rats. However, IschBM-MSC possessed higher fre-
quency of CFU-f than NormBM-MSC. These different
characteristics did not influence the effect of NormBM-
MSC Cm and IschBM-MSC Cm on cortical neuron. In
vitro experiment demonstrates that both NormBM-MSC
Cm and IschBM-MSC Cm significantly increased cor-
tical neuronal survival and promoted neuronal connec-
tion compared with medium control. These results
suggest that both NormBM-MSC Cm and IschBM-MSC
Cm promoted cell integrity and might decrease cell sus-
ceptibility after CNS injury. There is no significant dif-
ference between NormBM-MSC Cm and IschBM-MSC
Cm.
We further examined the effects of NormBM-MSC
Cm and IschBM-MSC Cm on rat subjected to ischemicstroke. In vivo data shows that both NormBM-MSC Cm
and IschBM-MSC Cm improved neurological outcome
but did not reduce the ischemic lesion. Recently,
Zacharek et al., elucidated that treatment of stroke with
BM-MSCs derived from stroke rats were better than
normal population due to the enhanced increasing of
angiogenesis and arteriogenesis via Ang1/Tie2 system as
well as neurological outcomes [29]. However, we found
that the recovery of neurological function after ischemic
stroke was not significant different between NormBM-
MSC Cm and IschBM-MSC Cm. Accumulating evi-
dence has suggested that BM-MSC promote endogenous
neurogenesis to improve functional recovery after stroke
in rats [7,30]. Our data shows that NormBM-MSC Cm
and IschBM-MSC Cm substantially increased neuronal
progenitor cells (DCX-positive cells) surrounding lateral
ventricle in stroke-affected hemisphere. Intriguingly,
Figure 5 Promoted sprouting of neuronal progenitor cells in the lateral ventricles of MCAo rats treated with NormBM-MSC Cm and
IschBM-MSC Cm. (A) The schematic picture displays the assessed lateral ventricle near hippocampus; Coronal sections of brain tissues from
different treatment were immunostained with anti-doublecortin (DCX; green). DCX-positive cells were located along with lateral ventricles in the
group given with BM-MSC Cm; magnification 200× (B): The immunoreactive area of DCX-positive cells was determined using Image-Pro Plus
software. Representative data were taken as the means ± S.D. of three repetitions.
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cantly attenuated microglia/macrophage infiltration in the
ischemic brain.
Together, results shown in the current study indicate
that treatment with NormBM-MSC Cm and IschBM-
MSC Cm after stroke significantly improved functional
outcome but did not substantially decrease cerebralinfarction. Enhancement of neurogenesis and attenuating
microglia/macrophage infiltration may contribute to the
observed improvement of functional outcome. Our find-
ings indicate the potential of BM-MSC Cm on treatment
of ischemic stroke. Patient’s age and morbidity may influ-
ence the BM-MSC effects [31,32]. In addition, the autolo-
gous BM-MSC requires harvesting bone marrow cells
Figure 6 Attenuated infiltration of microglia/macrophage in the cortical regions of MCAo rats given NormBM-MSC Cm and IschBM-
MSC Cm. (A) The illustration indicated the cortical region of the brain tissue was examined. Coronal sections of brain tissue were immunostained
with anti-ED1 antibody labeled FITC. Immunofluorescent showed that ED-1 positive cells were abundant in the ischemic cortex on day 7 after
MCAo (Control), whereas ED-1 positive cells were fewer in the group given NormBM-MSC Cm or IschBM-MSC Cm. ED-1 positive cells were absent
in the unaffected hemisphere after MCAo. (B) The numbers of ED1 immunoreactive cells were determined using Image-Pro Plus software.
Representative data were taken as the means ± S.D. of three repetitions.
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http://www.jbiomedsci.com/content/21/1/5from patients with stroke and subsequent culturing for
several days [33]. Allogeneic cells can be obtained from
young, healthy donors, ex vivo expanded and stored for
immediate use when needed [32,33]. Furthermore, our
data suggests that the efficiency is equal by using BM-
MSC Cm derived from patients with stroke or from a
normal population. Our results point out that the BM-
MSC Cm from an ischemic animal is not better than
from normal one for the treatment of stroke. The presentarticle adds to the issues under consideration that BM-
MSC behaves as extracorporeal bioreactors to produce
bioactive factors in the form of several effective com-
pounds contained in conditioned medium that may be-
come a novel therapeutic strategy for clinical use on
ischemic stroke. Our results conclude that use of BM-
MSC Cm from an ischemic animal for the treatment of
stroke has equal efficiency as compare with BM-MSC
Cm from a normal one.
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Additional file 1: Figure S1. Analysis and Identification of soluble
factors released to conditioned media of NormBM-MSC and IschBM-MSC.
(a) Representative gel electrophoretic analysis of Cm from NormBM-MSC
and IschBM-MSC (15 ul Cm/lane) (b) Representative gelatin-Zymographic
analysis of Cm from NormBM-MSC and IschBM-MSC (5 ul Cm/lane) (c)
Representative western blot analysis of Cm from NormBM-MSC and
IschBM-MSC (7.5 ul Cm/lane). SCF stands for stem cell factor; TIMP 1
stands for tissue inhibitor of metalloproteinase 1. VEGF is the abbreviation
of vascular endothelial growth factor; IGFBP4 is the abbreviation of
insulin-like growth factor-binding protein 4. aFGF stands for acidic
fibroblast growth factor.
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